Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07213817 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

A Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, sponsored by Ipsen.

Recruiting
Registry status
Phase 1
Development phase
114
Enrollment target
12
Study locations

NCT07213817: Recruiting Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, sponsored by Ipsen.

NCT07213817 is a Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor that is actively recruiting participants, run by Ipsen. The registered enrollment target is 114 participants, below the 190-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (40% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07213817, a Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, is actively recruiting participants, sponsored by Ipsen.

RECRUITING
Registry status
Phase 1
Development phase
114 participants
Enrollment target
12
Study locations

Study Summary

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phases: * Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose). * Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance). Study Periods: Screening: Up to 28 days before first IPN60300 injection to determine eligibility. Treatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor. Participants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.

Conditions Studied

Metastatic Solid Tumor Locally Advanced Solid Tumor

Interventions

  • BIOLOGICAL IPN60300

Study Locations (12)

Other

  • Centre Leon Berard - Lyon
  • Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau - Saint-Herblain
  • Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy) - Villejuif
  • Hospital Universitari Vall d'Hebron - Barcelona
  • NEXT Quiron-Barcelona - Barcelona
  • START Madrid CIOCC Hospital Universitario HM Sanchinarro - Madrid

Texas

  • MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Connecticut

  • Yale Cancer Center-Yale University - New Haven

Michigan

  • START Midwest - Grand Rapids

Pennsylvania

  • Sidney Kimmel Cancer Center - Philadelphia

Virginia

  • NEXT Oncology - Fairfax

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2025-12-05
Est. Completion 2028-10-30
Phase Phase 1
Ipsen

85 total trials

What NCT07213817 shows while recruiting

NCT07213817 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 190-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (40% lower).

The record links to 2 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IPN60300 is the first listed.

NCT07213817 lists 12 locations in 6 states (Other, Texas, Connecticut).

Frequently Asked Questions

What is clinical trial NCT07213817 about?

NCT07213817 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours". This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phase...

What is the current status of trial NCT07213817?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2025-12-05. Estimated completion is 2028-10-30.

What conditions does trial NCT07213817 study?

This clinical trial studies the following conditions: Metastatic Solid Tumor, Locally Advanced Solid Tumor.

What interventions are being tested in trial NCT07213817?

The interventions under investigation include: IPN60300 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07213817?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07213817 being conducted?

This trial has 12 study locations across Connecticut, Michigan, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07213817's enrollment target sits among peer trials

114 28th of 52 higher than 25 of 52 other Metastatic Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04522791 · 114 participants · Phase 2

    Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

  • NCT04875052 · 114 participants · NA

    Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

  • NCT05100342 · 114 participants

    Prospective Validation of a Points Score System Predicting 30-day Survival

  • NCT05224089 · 114 participants · Phase 4

    Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07213817

Source: ClinicalTrials.gov NCT07213817, the US trial registry maintained by the National Library of Medicine. NCT07213817 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.